Susan O'Brien
O'Brien, Susan, 1954-
O'Brien, Susan M. 1954-
O'Brien, Susan M.
VIAF ID: 41324176 (Personal)
Permalink: http://viaf.org/viaf/41324176
Preferred Forms
- 200 _ | ‡a O'Brien ‡b Susan M.
- 100 1 _ ‡a O'Brien, Susan M. ‡d 1954-
- 100 1 _ ‡a O'Brien, Susan M. ‡d 1954-
-
- 100 1 _ ‡a O'Brien, Susan, ‡d 1954-
-
-
- 100 0 _ ‡a Susan O'Brien
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Chronic lymphocytic leukemia, c2008: | |
Chronic myelogenous leukemia, version 1.2015. | |
Management of hematologic malignancies | |
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients | |
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | |
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System | |
Proteomics-based prediction of clinical response in acute myeloid leukemia | |
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate | |
Questions regarding frontline therapy of acute myeloid leukemia | |
Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay | |
Recent advances in de novo CD5+ diffuse large B cell lymphoma | |
Results of a phase 1-2 study of clofarabine in combination with cytarabine | |
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia | |
Rituximab in relapsed or refractory hairy cell leukemia | |
The role of gemtuzumab ozogamicin in acute leukaemia therapy | |
Role of leukemia cell invadosome in extramedullary infiltration | |
Role of the tumor microenvironment in mature B-cell lymphoid malignancies | |
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia | |
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | |
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia | |
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate | |
Signal transducer and activator of transcription | |
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response | |
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission | |
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase | |
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome | |
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal | |
STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis | |
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome | |
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate | |
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia | |
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells | |
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia | |
Targeting neuropilin-1 in human leukemia and lymphoma | |
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years | |
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens | |
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens | |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia | |
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase | |
Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance | |
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome | |
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience | |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up | |
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy | |
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy | |
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome |